NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)

Very nice to note that Alina Freiman Khaikin, Ph.D. will be presenting with top specialists in the field at the International, 3rd MOVE Symposium... #MOVE2025 #NurExone #ExtracellularVesicles #Tartu #EU

#LaborDay #Biotech #NeuroRecovery

The potential of regenerative medicine to help with conditions we don't have answers to! That theme was front and center when Jeremy E. of Regen Report - Regenerative Medicine News spoke with Lior Shaltiel, PhD, about our exciting regenerative medicine under development. Trailer below! Full interview: https://lnkd.in/dT94d9sY

Q2/2025: Executing our plan to advance the development of ExoPTEN ! • Broadened the evidence base supporting ExoPTEN for patients with acute spinal cord injury • Strengthened resources and exosome manufacturing readiness • Increased strategic visibility • On track for a 2026 Phase 1/2a, subject to regulatory review Read here ➡️ https://lnkd.in/daCWy9FR

New Preclinical Evidence Consistent with Spinal Cord Repair! New Financing! 📰 Preclinical image analysis indicates structural repair in injured spinal cords following ExoPTEN treatment!! Importantly, the data is from the same cohort of animals in which 100% of animals in a higher-dose group regained motor function (July 2025). 💼 Financing: We closed a C$0.78M non-brokered private placement (subject to TSXV approval) to support operations and advance ExoPTEN toward first-in-human studies. 📄 Full news release: https://lnkd.in/d65eH_Nw #SpinalCordInjury #RegenerativeMedicine #Exosomes #Neuroscience #Biotech #Preclinical #MRI #DTI #Investing #TSXV #OTCQB #FSE #NurExone #ExoPTEN

🪄 The people behind the science behind the magic 🪄 Thanks to Eureka Healthcare for highlighting our team in their cover story: "Architects of Tomorrow’s Regenerative Medicine Breakthroughs" Read here: https://lnkd.in/efeBNUwb

The Science Behind the Magic ✨ Drug Discovery World took a deep look at the mechanisms behind our exosome therapy, designed to help damaged nerves regenerate, rewire and recover, and what it takes to translate to clinical . Read more: https://lnkd.in/eZGVGhUZ

NurExone’s exosomes show strong healing potential for both the therapeutic and aesthetic markets! The bioanalysis of an independent study of our exosomes compared with an industry reference showed: 🧠 Nerve-repair signals: ~1.8× higher vs. reference 🛡️ Anti-inflammatory signals: ~2× higher 🩹 Wound-healing signals: ~2× higher 💡 Why it matters: Stronger healing signals suggest potential for better nerve repair and faster wound healing. Read the full release: https://lnkd.in/dhvPE_MC

🚀 NurExone Biologic has been named a Finalist at Falling Walls Venture 2025, joining a global stage of breakthrough science start-ups this November in Berlin. Huge thanks to the Falling Walls Foundation!! Read more: https://lnkd.in/dCdTNCQN #Excitingtechnology #Unmetmedicalneeds #Exosometherapies

🎙️Many thanks to Matthew Liteplo for hosting Lior Shaltiel, PhD on the OTCQB Podcast for entrepreneurs and innovators. We discuss exosomes as the ultimate drug‑delivery system and NurExone’s drive to restore lost function for patients with CNS injuries. 🎧 Catch the 12‑min episode here → https://lnkd.in/d8tHtNG7 #Exosomes #DrugDelivery #NeuroRegen #CNS #Biotech #ExoPTEN